Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Levocetirizine in Children 2-6 Years with Allergic Rhinitis
NCT00152412Phase 2Completed
- Sponsor
- UCB
- Start
- Jun 2004
- Primary completion
- Dec 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of levocetirizine in allergic rhinitis (AR), sponsored by UCB. Primary endpoint: Safety of levocetirizine at 4 weeks. Started Jun 2004; status: completed.
02
Drugs
levocetirizine
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT00152412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152412.